On the public citation graph
Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study
0 signed · 143 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/hep.23116openalex-snapshot
Importance of Changes in Adipose Tissue Insulin Resistance to Histological Response During Thiazolidinedione Treatment of Patients with Nonalcoholic Steatohepatitis†
inferredcites →https://doi.org/10.1002/hep.23569openalex-snapshot
Glucagon-Like Peptide-1 Receptor Is Present on Human Hepatocytes and Has A Direct Role in Decreasing Hepatic Steatosis in Vitro by Modulating Elements of the Insulin Signaling Pathway
inferredcites →https://doi.org/10.1002/hep.25739openalex-snapshot
Nonalcoholic steatohepatitis versus steatosis: Adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism
inferredcites →https://doi.org/10.1002/hep.25805openalex-snapshot
Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: A pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study
inferredcites →https://doi.org/10.1002/hep.28287openalex-snapshot
Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease
inferredcites →https://doi.org/10.1007/s00125-005-0107-1openalex-snapshot
Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005
inferredcites →https://doi.org/10.1007/s00125-012-2738-3openalex-snapshot
Direct effect of GLP-1 infusion on endogenous glucose production in humans
inferredcites →https://doi.org/10.1007/s001250100026openalex-snapshot
Human adipose tissue glucose uptake determined using [ 18 F]-fluoro-deoxy-glucose ([ 18 F]FDG) and PET in combination with microdialysis
inferredcites →https://doi.org/10.1007/s11892-015-0607-4openalex-snapshot
Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Common Pathophysiologic Mechanisms
inferredcites →https://doi.org/10.1007/s40265-012-0004-0openalex-snapshot
Nonalcoholic Fatty Liver Disease: Current Issues and Novel Treatment Approaches
inferredcites →https://doi.org/10.1016/j.autneu.2003.11.001openalex-snapshot
Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells
inferredcites →https://doi.org/10.1016/j.cgh.2009.05.033openalex-snapshot
Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1016/j.cmet.2013.04.008openalex-snapshot
Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action
inferredcites →https://doi.org/10.1016/j.jhep.2015.08.038openalex-snapshot
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
inferredcites →https://doi.org/10.1016/j.jhep.2015.11.004openalex-snapshot
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
inferredcites →https://doi.org/10.1016/j.jhep.2015.11.031openalex-snapshot
Time for Glucagon like peptide-1 receptor agonists treatment for patients with NAFLD?
inferredcites →https://doi.org/10.1016/j.molmet.2014.09.005openalex-snapshot
GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance
inferredcites →https://doi.org/10.1038/jcbfm.1983.1openalex-snapshot
Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data
inferredcites →https://doi.org/10.1038/jcbfm.1985.87openalex-snapshot
Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. Generalizations
inferredcites →https://doi.org/10.1038/sj.clpt.6100034openalex-snapshot
Effect of Pioglitazone on the Metabolic and Hormonal Response to a Mixed Meal in Type II Diabetes
inferredcites →https://doi.org/10.1053/j.gastro.2006.12.040openalex-snapshot
Quantification of Liver Glucose Metabolism by Positron Emission Tomography: Validation Study in Pigs
inferredcites →https://doi.org/10.1053/j.gastro.2007.04.007openalex-snapshot
Glucagon-Like Peptide-1 and Its Receptor Agonist Exendin-4 Modulate Cholangiocyte Adaptive Response to Cholestasis
inferredcites →https://doi.org/10.1053/j.gastro.2007.04.068openalex-snapshot
Relationship Between Hepatic/Visceral Fat and Hepatic Insulin Resistance in Nondiabetic and Type 2 Diabetic Subjects
inferredcites →https://doi.org/10.1111/dom.12272openalex-snapshot
Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non‐alcoholic steatohepatitis
inferredcites →https://doi.org/10.1111/j.1478-3231.2011.02462.xopenalex-snapshot
Glucagon‐like peptide‐1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high‐fat diet in nonalcoholic steatohepatitis
inferredcites →https://doi.org/10.1111/j.1478-3231.2011.02626.xopenalex-snapshot
Glucagon like‐peptide 1 receptor and the liver
inferredcites →https://doi.org/10.1111/jgh.13026openalex-snapshot
Incretin‐based therapies for the treatment of non‐alcoholic fatty liver disease: A systematic review and meta‐analysis
inferredcites →https://doi.org/10.1136/bmj.d7771openalex-snapshot
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
inferredcites →https://doi.org/10.1152/ajpendo.00024.2003openalex-snapshot
Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect
inferredcites →https://doi.org/10.1152/ajpendo.00030.2008openalex-snapshot
Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes
inferredcites →https://doi.org/10.1152/ajpendo.00244.2014openalex-snapshot
Hepatic portal vein denervation impairs oral glucose tolerance but not exenatide’s effect on glycemia
inferredcites →https://doi.org/10.1152/ajpgi.00121.2005openalex-snapshot
Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors
inferredcites →https://doi.org/10.1152/jappl.1999.87.5.1813openalex-snapshot
Assessment of methods for improving tracer estimation of non-steady-state rate of appearance
inferredcites →https://doi.org/10.1161/atvbaha.112.246207openalex-snapshot
Exenatide, a Glucagon-like Peptide-1 Receptor Agonist, Acutely Inhibits Intestinal Lipoprotein Production in Healthy Humans
inferredcites →https://doi.org/10.1172/jci78371openalex-snapshot
Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight
inferredcites →https://doi.org/10.1186/1471-230x-10-98openalex-snapshot
A simple index of lipid overaccumulation is a good marker of liver steatosis
inferredcites →https://doi.org/10.1210/en.134.5.2156openalex-snapshot
Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse
inferredcites →https://doi.org/10.1210/en.137.7.2968openalex-snapshot
Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
inferredcites →https://doi.org/10.1210/en.2006-0153openalex-snapshot
Glucagon-Like Peptide-1 (GLP-1) Receptors Expressed on Nerve Terminals in the Portal Vein Mediate the Effects of Endogenous GLP-1 on Glucose Tolerance in Rats
inferredcites →https://doi.org/10.1210/en.2008-0945openalex-snapshot
The Glucagon-Like Peptide-1 Receptor Regulates Endogenous Glucose Production and Muscle Glucose Uptake Independent of Its Incretin Action
inferredcites →https://doi.org/10.1210/en.2011-0174openalex-snapshot
Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4
inferredcites →https://doi.org/10.1210/en.2012-1937openalex-snapshot
GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic Male ApoE−/− Mice
inferredcites →https://doi.org/10.1210/en.2013-1934openalex-snapshot
GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
inferredcites →https://doi.org/10.1210/jc.2010-2146openalex-snapshot
Effect of Exenatide on Splanchnic and Peripheral Glucose Metabolism in Type 2 Diabetic Subjects
inferredcites →https://doi.org/10.2337/db13-0321openalex-snapshot
Long-Term Effects of Bariatric Surgery on Meal Disposal and β-Cell Function in Diabetic and Nondiabetic Patients
inferredcites →https://doi.org/10.2337/db14-1718openalex-snapshot
Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated With Glucose Homeostasis and Reward System
inferredcites →https://doi.org/10.2337/diabetes.50.8.1720openalex-snapshot
Glucose Competence of the Hepatoportal Vein Sensor Requires the Presence of an Activated Glucagon-Like Peptide-1 Receptor
inferredcites →https://doi.org/10.3748/wjg.v20.i10.2653openalex-snapshot
Exenatide improves hepatic steatosis by enhancing lipid use in adipose tissue in nondiabetic rats
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4771342openalex-extracted
Evaluating the Effect of Dual GIPR/GLP-1R Agonists on Non-Alcoholic Fatty Liver Disease and Metabolic Risk Abnormalities: A Drug-Target Mendelian Randomization Study
inferred← citeshttps://doi.org/10.1002/adtp.202400400openalex-snapshot
Recent Advances in Promoting Bone Regeneration in Type 2 Diabetes Using Drug Delivery Vehicles and Vehicle‐Free Therapeutics
inferred← citeshttps://doi.org/10.1002/hep.30429openalex-snapshot
Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.1007/978-3-319-61013-9_4openalex-snapshot
Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes
inferred← citeshttps://doi.org/10.1007/978-3-319-95828-6_17openalex-snapshot
Pharmacological Options for NASH
inferred← citeshttps://doi.org/10.1007/978-3-319-95828-6_4openalex-snapshot
NAFLD and Insulin Resistance: A Multisystemic Disease
inferred← citeshttps://doi.org/10.1007/s00125-020-05157-wopenalex-snapshot
Insulin sensitivity depends on the route of glucose administration
inferred← citeshttps://doi.org/10.1007/s00125-021-05442-2openalex-snapshot
Liver-targeting drugs and their effect on blood glucose and hepatic lipids
inferred← citeshttps://doi.org/10.1007/s00125-023-06055-7openalex-snapshot
Advances and challenges in measuring hepatic glucose uptake with FDG PET: implications for diabetes research
inferred← citeshttps://doi.org/10.1007/s00592-024-02300-6openalex-snapshot
GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes
inferred← citeshttps://doi.org/10.1007/s11739-026-04384-0openalex-snapshot
Effects of glucagon-like peptide-1 receptor agonists and dual glucagon-like peptide-1 receptor agonists/glucose-dependent insulinotropic polypeptide on liver stiffness and steatosis evaluated through Fibroscan®: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s13105-021-00835-8openalex-snapshot
Exendin-4 may improve type 2 diabetes by modulating the epigenetic modifications of pancreatic histone H3 in STZ-induced diabetic C57BL/6 J mice
inferred← citeshttps://doi.org/10.1007/s13300-018-0449-6openalex-snapshot
A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss
inferred← citeshttps://doi.org/10.1007/s40265-017-0706-4openalex-snapshot
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
inferred← citeshttps://doi.org/10.1016/b978-0-443-27370-4.00023-8openalex-snapshot
Pharmacologic intervention of nonalcoholic steatohepatitis and related cirrhosis
inferred← citeshttps://doi.org/10.1016/j.addr.2018.11.007openalex-snapshot
Molecular imaging of diabetes and diabetic complications: Beyond pancreatic β-cell targeting
inferred← citeshttps://doi.org/10.1016/j.bcp.2022.115337openalex-snapshot
Adipose tissue mitochondrial dysfunction and cardiometabolic diseases: On the search for novel molecular targets
inferred← citeshttps://doi.org/10.1016/j.diabres.2025.112288openalex-snapshot
Hepatic steatosis is associated with impaired hepatic glucose uptake under hyperglycemic conditions, a dynamic whole-body 18F-FDG PET approach
inferred← citeshttps://doi.org/10.1016/j.eprac.2024.11.017openalex-snapshot
Comparison of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter Protein-2 Inhibitors on Treating Metabolic Dysfunction-Associated Steatotic Liver Disease or Metabolic Dysfunction-Associated Steatohepatitis: Systematic Review and Network Meta-Analysis of Randomised…
inferred← citeshttps://doi.org/10.1016/j.intimp.2026.116416openalex-snapshot
Exenatide through PPARδ improved hepatic insulin resistance in patients of type 2 diabetes mellitus via suppressing pyroptosis
inferred← citeshttps://doi.org/10.1016/j.jhep.2017.11.014openalex-snapshot
Lipotoxicity and the gut-liver axis in NASH pathogenesis
inferred← citeshttps://doi.org/10.1016/j.jhep.2019.06.031openalex-snapshot
Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1016/j.jhep.2022.04.002openalex-snapshot
Breakthroughs in therapies for NASH and remaining challenges
inferred← citeshttps://doi.org/10.1016/j.jhepr.2019.07.002openalex-snapshot
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
inferred← citeshttps://doi.org/10.1016/j.kint.2023.10.014openalex-snapshot
Anti-obesity pharmacotherapy in adults with chronic kidney disease
inferred← citeshttps://doi.org/10.1016/j.metabol.2018.11.014openalex-snapshot
Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
inferred← citeshttps://doi.org/10.1016/j.metabol.2020.154203openalex-snapshot
Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis
inferred← citeshttps://doi.org/10.1016/j.molmet.2020.101158openalex-snapshot
Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment?
inferred← citeshttps://doi.org/10.1016/j.obmed.2026.100712openalex-snapshot
Nanotechnology-enabled targeted delivery of incretin therapies for the treatment of obesity and metabolic disorders
inferred← citeshttps://doi.org/10.1016/j.peptides.2017.12.010openalex-snapshot
Intestinal peptide changes after bariatric and minimally invasive surgery: Relation to diabetes remission
inferred← citeshttps://doi.org/10.1016/j.peptides.2021.170597openalex-snapshot
A synthetic peptide AWRK6 ameliorates metabolic associated fatty liver disease: involvement of lipid and glucose homeostasis
inferred← citeshttps://doi.org/10.1016/j.phrs.2018.09.025openalex-snapshot
Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
inferred← citeshttps://doi.org/10.1016/j.soard.2021.04.022openalex-snapshot
The relation between postprandial glucagon-like peptide-1 release and insulin sensitivity before and after bariatric surgery in humans with class II/III obesity
inferred← citeshttps://doi.org/10.1016/j.tem.2018.03.014openalex-snapshot
Prevention and Treatment of Type 2 Diabetes: A Pathophysiological-Based Approach
inferred← citeshttps://doi.org/10.1016/j.tem.2022.03.005openalex-snapshot
SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease
inferred← citeshttps://doi.org/10.1016/j.xcrm.2022.100813openalex-snapshot
Anti-diabetic effects of GLP1 analogs are mediated by thermogenic interleukin-6 signaling in adipocytes
inferred← citeshttps://doi.org/10.1016/s2213-8587(22)00070-5openalex-snapshot
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
inferred← citeshttps://doi.org/10.1038/s12276-022-00851-8openalex-snapshot
Metabolic improvement and liver regeneration by inhibiting CXXC5 function for non-alcoholic steatohepatitis treatment
inferred← citeshttps://doi.org/10.1038/s41366-020-0592-9openalex-snapshot
Usefulness of surrogate markers to determine insulin action in fat cells
inferred← citeshttps://doi.org/10.1038/s41467-019-14003-6openalex-snapshot
Identification of osteoclast-osteoblast coupling factors in humans reveals links between bone and energy metabolism
inferred← citeshttps://doi.org/10.1038/s41575-023-00830-yopenalex-snapshot
The intestine as an endocrine organ and the role of gut hormones in metabolic regulation
inferred← citeshttps://doi.org/10.1038/s41575-023-00888-8openalex-snapshot
Hepatic glucose metabolism in the steatotic liver
inferred← citeshttps://doi.org/10.1038/s41598-017-08444-6openalex-snapshot
Muscle and adipose tissue morphology, insulin sensitivity and beta-cell function in diabetic and nondiabetic obese patients: effects of bariatric surgery
inferred← citeshttps://doi.org/10.1042/bcj20190462openalex-snapshot
Identification and characterization of adipose surface epitopes
inferred← citeshttps://doi.org/10.1089/met.2019.0102openalex-snapshot
Acute Exenatide Therapy Attenuates Postprandial Vasodilation in Humans with Prediabetes: A Randomized Controlled Trial
inferred← citeshttps://doi.org/10.1089/met.2021.0055openalex-snapshot
Non-Alcoholic Steatohepatitis Severity Associates with FGF21 Level and Kidney Glucose Uptake
inferred← citeshttps://doi.org/10.1097/tp.0000000000002483openalex-snapshot
Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis
inferred← citeshttps://doi.org/10.1101/2023.09.20.23295840openalex-snapshot
Endogenous glucagon-like peptide 1 diminishes prandial glucose counterregulatory response to hypoglycemia after gastric bypass surgery
inferred← citeshttps://doi.org/10.1101/2023.10.22.23297377openalex-snapshot
GLP-1 enhances beta-cell response to protein ingestion independent of glycemia and bariatric surgery amplifies it
inferred← citeshttps://doi.org/10.1111/apt.14210openalex-snapshot
Review article: new treatments in non‐alcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1111/cen.13454openalex-snapshot
Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome
inferred← citeshttps://doi.org/10.1111/dom.12836openalex-snapshot
Effect of exenatide on postprandial glucose fluxes, lipolysis, and ß‐cell function in non‐diabetic, morbidly obese patients
inferred← citeshttps://doi.org/10.1111/dom.14196openalex-snapshot
A look to the future in non‐alcoholic fatty liver disease: Are glucagon‐like peptide‐1 analogues or sodium‐glucose co‐transporter‐2 inhibitors the answer?
inferred← citeshttps://doi.org/10.1111/dom.15359openalex-snapshot
Efficacy of beinaglutide in the treatment of hepatic steatosis in type 2 diabetes patients with nonalcoholic fatty liver disease: A randomized, open‐label, controlled trial
inferred← citeshttps://doi.org/10.1111/dom.15570openalex-snapshot
Differential effect of endogenous glucagon‐like peptide‐1 on prandial glucose counterregulatory response to hypoglycaemia in humans with and without bariatric surgery
inferred← citeshttps://doi.org/10.1152/physiol.00023.2018openalex-snapshot
Oxidative Stress, Intrauterine Growth Restriction, and Developmental Programming of Type 2 Diabetes
inferred← citeshttps://doi.org/10.1155/2018/4019248openalex-snapshot
Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance
inferred← citeshttps://doi.org/10.1155/ije/6332117openalex-snapshot
The Effect of Exenatide on Platelets Ratio Index and Fibrosis‐4 Index in Obese Patients With Diabetes Mellitus
inferred← citeshttps://doi.org/10.1172/jci.insight.93091openalex-snapshot
Exenatide regulates pancreatic islet integrity and insulin sensitivity in the nonhuman primate baboon Papio hamadryas
inferred← citeshttps://doi.org/10.1172/jci143861openalex-snapshot
An abundant biliary metabolite derived from dietary omega-3 polyunsaturated fatty acids regulates triglycerides
inferred← citeshttps://doi.org/10.1186/s12986-023-00748-xopenalex-snapshot
Pharmacotherapies of NAFLD: updated opportunities based on metabolic intervention
inferred← citeshttps://doi.org/10.1186/s13098-020-00570-yopenalex-snapshot
NAFLD as a continuum: from obesity to metabolic syndrome and diabetes
inferred← citeshttps://doi.org/10.1186/s13578-020-00507-yopenalex-snapshot
Multiple organs involved in the pathogenesis of non-alcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1210/clinem/dgaf336openalex-snapshot
Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis
inferred← citeshttps://doi.org/10.1210/endrev/bnz009openalex-snapshot
Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management
inferred← citeshttps://doi.org/10.1210/jc.2018-00433openalex-snapshot
Youth With Type 1 Diabetes Have Adipose, Hepatic, and Peripheral Insulin Resistance
inferred← citeshttps://doi.org/10.1515/hmbci-2017-0060openalex-snapshot
The color of fat and its central role in the development and progression of metabolic diseases
inferred← citeshttps://doi.org/10.1530/joe-19-0007openalex-snapshot
Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis
inferred← citeshttps://doi.org/10.1556/650.2022.32480openalex-snapshot
A nem alkoholos zsírmájbetegség és a 2-es típusú cukorbetegség.
inferred← citeshttps://doi.org/10.2174/0929867324666171009115356openalex-snapshot
Fighting Type-2 Diabetes: Present and Future Perspectives
inferred← citeshttps://doi.org/10.2214/ajr.18.20012openalex-snapshot
Pilot Study to Diagnose Nonalcoholic Steatohepatitis With Dynamic 18 F-FDG PET
inferred← citeshttps://doi.org/10.2337/db23-0972openalex-snapshot
GLP-1 Receptor Agonist Treatment Improves Fasting and Postprandial Lipidomic Profiles Independently of Diabetes and Weight Loss
inferred← citeshttps://doi.org/10.2337/db24-0406openalex-snapshot
Effect of Hyperketonemia on Myocardial Function in Patients With Heart Failure and Type 2 Diabetes
inferred← citeshttps://doi.org/10.23736/s1120-4826.20.02619-1openalex-snapshot
Molecular mechanisms of hepatic fibrosis in chronic liver diseases
inferred← citeshttps://doi.org/10.2478/ahem-2023-0001openalex-snapshot
GLP-1 analogues in the treatment of obesity and non-alcoholic fatty liver disease
inferred← citeshttps://doi.org/10.26481/dis.20230125avopenalex-snapshot
Improving flexibility in substrate metabolism
inferred← citeshttps://doi.org/10.3389/fendo.2018.00649openalex-snapshot
Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
inferred← citeshttps://doi.org/10.3389/fendo.2021.696977openalex-snapshot
The Postprandial Glycaemic and Hormonal Responses Following the Ingestion of a Novel, Ready-to-Drink Shot Containing a Low Dose of Whey Protein in Centrally Obese and Lean Adult Males: A Randomised Controlled Trial
inferred← citeshttps://doi.org/10.3389/fendo.2021.769069openalex-snapshot
Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.3389/fendo.2022.1012904openalex-snapshot
Exenatide improves hepatocyte insulin resistance induced by different regional adipose tissue
inferred← citeshttps://doi.org/10.3389/fphar.2018.01168openalex-snapshot
GLP-1 Improves Adipocyte Insulin Sensitivity Following Induction of Endoplasmic Reticulum Stress
inferred← citeshttps://doi.org/10.3389/fphar.2023.1088670openalex-snapshot
PEGylated exenatide injection (PB-119) improves beta-cell function and insulin resistance in treatment-naïve type 2 diabetes mellitus patients
inferred← citeshttps://doi.org/10.3390/clinpract15070128openalex-snapshot
A Case Series on the Efficacy of the Pharmacological Treatment of Lipedema: The Italian Experience with Exenatide
inferred← citeshttps://doi.org/10.3390/ijms21165820openalex-snapshot
Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH
inferred← citeshttps://doi.org/10.3390/ijms23052659openalex-snapshot
Evidence of a Gastro-Duodenal Effect on Adipose Tissue and Brain Metabolism, Potentially Mediated by Gut–Liver Inflammation: A Study with Positron Emission Tomography and Oral 18FDG in Mice
inferred← citeshttps://doi.org/10.3390/ijms241210164openalex-snapshot
Novel Antidiabetic Agents and Their Effects on Lipid Profile: A Single Shot for Several Cardiovascular Targets
inferred← citeshttps://doi.org/10.3390/ijms241411271openalex-snapshot
Role of Oxidative Stress and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 in Nonalcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.3390/ijms25115640openalex-snapshot
Metabolic Dysfunction–Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options
inferred← citeshttps://doi.org/10.3390/jpm11060499openalex-snapshot
Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives
inferred← citeshttps://doi.org/10.3390/toxins18070286openalex-snapshot
Animal Venoms Targeting Cellular Mechanisms: Advances and Implications for Drug Discovery and Disease Therapy
inferred← citeshttps://doi.org/10.37349/eemd.2025.101443openalex-snapshot
Clinical management strategies for type 2 diabetes mellitus with metabolic dysfunction-associated fatty liver disease: an umbrella review of systematic reviews and meta-analyses
inferred← citeshttps://doi.org/10.3945/ajcn.117.157248openalex-snapshot
Duodenal and ileal glucose infusions differentially alter gastrointestinal peptides, appetite response, and food intake: a tube feeding study
inferred← citeshttps://doi.org/10.4254/wjh.v12.i8.493openalex-snapshot
Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.